about
Substance abuse and schizophrenia: pharmacotherapeutic interventionEnhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout miceSocial problem-solving abilities and personality disorder characteristics among dual-diagnosed persons in substance abuse treatment.Developmental and neurologic correlates of treatment response in schizophreniaCannabis use and psychosis: a review of clinical and epidemiological evidence.Potential benefits of quetiapine in the treatment of substance dependence disordersMental illness and substance misuse: a nursing challenge.Treatment of the special patient with schizophrenia.Pharmacotherapy for schizophrenia and co-occurring substance use disorders.Suicide risk in schizophrenia: learning from the past to change the future.Enhancing readiness-to-change substance abuse in persons with schizophrenia. A four-session motivation-based intervention.Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use DisordersTen-year recovery outcomes for clients with co-occurring schizophrenia and substance use disorders.Cannabis, cannabinoids and schizophrenia: integration of the evidence.Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications: a case reportPsychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system?The co-occurrence of mania with medical and other psychiatric disorders.Associations between psychotic symptoms and substance use in young offenders.Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics.Lifetime history of substance misuse in first-episode psychosis: prevalence and its influence on psychopathology and onset of psychotic symptoms.Clozapine treatment in patients with prior substance abuse.Aripiprazole reduces alcohol use.Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder.Relationship between concurrent substance abuse in psychiatric patients and neuroleptic dosage.
P2860
Q24621711-3E82CB0B-E5E1-49F4-95B2-06B90E4373A1Q28482464-952E2E69-B730-4996-815D-3DB9301994E8Q32041768-174FDA95-5A9A-4995-BDFC-31B23F1E2050Q33921005-7B5D5889-D59B-4985-9B02-5F43AD712415Q33933884-9476B08B-0251-4617-BD44-5EB77A7C8F29Q34554089-BCE454E7-87CD-4068-939E-FF32CF4FCDF9Q34779082-A7015EBF-BDCB-44E9-9135-BF5B2AA3E7BEQ35236370-B01804FC-8995-4E8D-B66B-AD190E512703Q35294697-A989851D-D86E-44F2-B4FD-2DB3CA41FF5AQ35738863-E017D8C8-8544-4DD4-9DE5-6336BAFC8739Q36731668-03A259A8-50FE-469F-9EB8-5F6D560C2843Q36927085-B980083A-26FA-414F-922C-D264E279D277Q37075908-2C677537-AE54-4635-A694-0FDBAA026A6DQ37160448-6174E180-F31B-4D59-87C5-B62A54836B4EQ37233407-552DC231-BC26-411C-BCAD-F23B34F74C24Q38016975-3F61A05F-7BB1-41D8-A041-0B37CB37EA58Q40517742-2D9DF064-AAB5-41AE-A2EB-20264B0B5D70Q40826238-30F364B5-7F4C-4945-A871-BB27BE9D25A5Q42163532-65CC1EB8-AB4E-4C28-92E1-D2D873131ABAQ43808532-85732754-354D-4B44-AE6D-6CE26A906682Q44375190-DD9CC9D3-2C41-4859-8FB0-FF71B7A93A4BQ46494443-D03FE2B7-13E9-48F3-867E-70311BB37A76Q52016145-8BC8EF2D-06CE-46FE-A831-D49E2BAD2622Q52016666-02CE9630-2C23-4E06-A43C-C6135155062C
P2860
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Psychotogenic drug use and neuroleptic response.
@en
Psychotogenic drug use and neuroleptic response.
@nl
type
label
Psychotogenic drug use and neuroleptic response.
@en
Psychotogenic drug use and neuroleptic response.
@nl
prefLabel
Psychotogenic drug use and neuroleptic response.
@en
Psychotogenic drug use and neuroleptic response.
@nl
P2093
P356
P1476
Psychotogenic drug use and neuroleptic response.
@en
P2093
Bowers MB Jr
P356
10.1093/SCHBUL/16.1.81
P407
P577
1990-01-01T00:00:00Z